Jason Karlawish of the Perelman School of Medicine expressed skepticism about the FDA’s approval of a new Alzheimer’s disease drug. “Another study is needed to establish whether this drug, in fact, is effective. Unfortunately, the FDA approved the drug for marketing, although they also do want another study,” he said.